EA200601630A1 - Ниосома, имеющая внедрённый в неё маталлопорфириновый комплекс, способ её получения и лекарственное средство с её использованием - Google Patents
Ниосома, имеющая внедрённый в неё маталлопорфириновый комплекс, способ её получения и лекарственное средство с её использованиемInfo
- Publication number
- EA200601630A1 EA200601630A1 EA200601630A EA200601630A EA200601630A1 EA 200601630 A1 EA200601630 A1 EA 200601630A1 EA 200601630 A EA200601630 A EA 200601630A EA 200601630 A EA200601630 A EA 200601630A EA 200601630 A1 EA200601630 A1 EA 200601630A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- niosome
- metalloporphyrin complex
- complex embedded
- embedded
- niosoma
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Dispersion Chemistry (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Toxicology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Предложена ниосома, имеющая внедренный в нее металлопорфириновый комплекс, содержащий катионизированный металлопорфириновый комплекс и ниосомообразующее вещество. Ниосома, имеющая внедренный в нее металлопорфириновый комплекс, имеет SOD-активность, может взаимодействовать с супероксидными анионными радикалами (O·), являющимися мишенью, и может успешно уменьшать содержание указанных радикалов. Ниосома, имеющая внедренный в нее металлопорфириновый комплекс, может проникать в клетки живых организмов, такие как опухолевые клетки, благодаря свойствам ниосомы. Следовательно, ниосома, имеющая внедренный в нее металлопорфириновый комплекс, может оказывать благоприятное действие в терапии злокачественных новообразований за счет уменьшения O· в опухолевых клетках. Кроме того, поскольку эффект является селективным, ниосома может быть использована в качестве нового противоопухолевого средства без побочных действий. Более того, ниосома, имеющая внедренный в него металлопорфириновый комплекс, может удерживаться в крови, оказывая при этом превосходное антиоксидантное действие. Таким образом, ниосома может защищать живые организмы от неблагоприятных эффектов, вызываемых активными разновидностями кислорода.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2004/002750 WO2005084665A1 (ja) | 2004-03-04 | 2004-03-04 | 金属ポルフィリン錯体包埋ニオソーム、その製造法およびこれを利用する医薬 |
Publications (1)
Publication Number | Publication Date |
---|---|
EA200601630A1 true EA200601630A1 (ru) | 2007-02-27 |
Family
ID=34917824
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200601630A EA200601630A1 (ru) | 2004-03-04 | 2004-03-04 | Ниосома, имеющая внедрённый в неё маталлопорфириновый комплекс, способ её получения и лекарственное средство с её использованием |
Country Status (6)
Country | Link |
---|---|
US (2) | US20080269184A1 (ru) |
EP (1) | EP1731150A4 (ru) |
JP (1) | JP4669837B2 (ru) |
CN (1) | CN1942184A (ru) |
EA (1) | EA200601630A1 (ru) |
WO (1) | WO2005084665A1 (ru) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070172520A1 (en) * | 2005-11-18 | 2007-07-26 | University Of South Florida | Immunotargeting of Nonionic Surfactant Vesicles |
CN102311454B (zh) * | 2010-07-09 | 2014-06-04 | 哈尔滨工业大学 | 含卟啉环功能基团的复合脂质及其制备方法与用途 |
CN103068395A (zh) * | 2010-08-06 | 2013-04-24 | 汤浅真 | 疾病治疗药 |
KR101352565B1 (ko) | 2012-01-30 | 2014-01-17 | 서강대학교산학협력단 | 마그네슘 프로토포르피린 ix를 함유한 과산화수소 제거제 및 이를 이용한 과산화수소 독성의 저감 방법 |
US10328085B2 (en) | 2014-05-09 | 2019-06-25 | Uniwersytet Jagiellonski | Cobalt porphyrins for the treatment of blood-related disorders |
PL233504B1 (pl) | 2014-05-09 | 2019-10-31 | Univ Jagiellonski | Protoporfiryna IX kobaltu do stosowania w leczeniu neutropenii i białaczek |
EP3302436A4 (en) * | 2015-05-26 | 2019-01-02 | The General Hospital Corporation | Liposomal nanoconstructs and methods of making and using the same |
CN115040446A (zh) * | 2022-06-24 | 2022-09-13 | 曾会明 | 一种sod植物提取物护肤组合物、护肤品及其制备方法 |
WO2024073013A1 (en) * | 2022-09-28 | 2024-04-04 | Eresina, Llc | Combination treatment of dermal and transdermal fibrotic diseases, disorders and associated pain and inflammation |
CN115945220B (zh) * | 2023-03-15 | 2023-05-30 | 四川大学 | 一种Ir金属基生物催化剂及其制备方法和用途 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2571963B1 (fr) * | 1984-10-24 | 1987-07-10 | Oreal | Composition a usage cosmetique ou pharmaceutique contenant des niosomes et au moins un polyamide hydrosoluble et procede de preparation de cette composition. |
FR2597346B1 (fr) * | 1986-04-22 | 1989-08-18 | Oreal | Procede pour faciliter la formation de niosomes en dispersion dans une phase aqueuse et pour ameliorer leur stabilite et leur taux d'encapsulation, et dispersions correspondantes. |
DE68928607T2 (de) * | 1988-07-14 | 1998-07-23 | Toyohakka Kogyo K K | Porphyrinderivate |
US5010073A (en) * | 1989-10-05 | 1991-04-23 | The Rockefeller University | Use of liposomes as carriers for metalloporphyrins |
JPH04356420A (ja) * | 1991-05-31 | 1992-12-10 | Nisshin Flour Milling Co Ltd | チアミン・コバルト・クロロフィリン錯化合物含有組成物 |
JPH05229948A (ja) * | 1991-12-25 | 1993-09-07 | Asahi Chem Ind Co Ltd | 悪性腫瘍の治療剤または診断剤およびac8007物質の製造法 |
GB9404293D0 (en) * | 1994-03-04 | 1994-04-20 | Shuster Sam | Drug delivery system |
DE4421433C1 (de) * | 1994-06-18 | 1995-06-08 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit Wirkstoffen, die Kohlenmonoxid-Quellen darstellen, Verfahren zu seiner Herstellung und seine Verwendung |
JP2001511128A (ja) * | 1997-01-28 | 2001-08-07 | ファルマシア・アンド・アップジョン・カンパニー | 水不溶性ポルフィリンの脂質錯体の凍結乾燥物 |
AU6650198A (en) * | 1997-02-05 | 1998-08-25 | Board Of Regents, The University Of Texas System | Porphyrin compounds as telomerase inhibitors |
US6410782B1 (en) * | 1997-07-09 | 2002-06-25 | Geange Ltd. | Diphosphonic acid salts for the treatment of osteoporosis |
JP2000247978A (ja) * | 1999-02-25 | 2000-09-12 | Toyo Ink Mfg Co Ltd | 金属ポルフィリン錯体及びそれを含有してなる医薬組成物 |
US20020164379A1 (en) * | 2000-06-29 | 2002-11-07 | Toru Nishihara | Oxygen-containing ophthalmic composition |
ATE439134T1 (de) * | 2001-01-19 | 2009-08-15 | Nat Jewish Med & Res Center | Medikament zum schutz in der radiotherapie |
JP4741205B2 (ja) * | 2003-07-07 | 2011-08-03 | 真 湯浅 | 金属ポルフィリン錯体包埋リポソーム、その製造方法およびこれを利用する医薬 |
US20050008687A1 (en) * | 2003-07-07 | 2005-01-13 | Makoto Yuasa | Metal-porphyrin-complex-embedded liposomes, production process thereof, and medicines making use of the same |
-
2004
- 2004-03-04 WO PCT/JP2004/002750 patent/WO2005084665A1/ja active Application Filing
- 2004-03-04 US US10/591,658 patent/US20080269184A1/en not_active Abandoned
- 2004-03-04 CN CNA2004800429149A patent/CN1942184A/zh active Pending
- 2004-03-04 EP EP04717289A patent/EP1731150A4/en not_active Withdrawn
- 2004-03-04 EA EA200601630A patent/EA200601630A1/ru unknown
- 2004-03-04 JP JP2006510574A patent/JP4669837B2/ja not_active Expired - Fee Related
-
2011
- 2011-07-14 US US13/183,273 patent/US20120039987A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1731150A1 (en) | 2006-12-13 |
US20080269184A1 (en) | 2008-10-30 |
CN1942184A (zh) | 2007-04-04 |
JP4669837B2 (ja) | 2011-04-13 |
US20120039987A1 (en) | 2012-02-16 |
WO2005084665A1 (ja) | 2005-09-15 |
EP1731150A4 (en) | 2010-06-16 |
JPWO2005084665A1 (ja) | 2008-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Xu et al. | Metformin ameliorates ionizing irradiation-induced long-term hematopoietic stem cell injury in mice | |
EA201201186A1 (ru) | ИСПОЛЬЗОВАНИЕ ErbB3 ИНГИБИТОРОВ В ЛЕЧЕНИИ ТРИЖДЫ НЕГАТИВНОГО И БАЗАЛЬНО-ПОДОБНОГО ВИДОВ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ | |
TR201903587T4 (tr) | Telomeraz aktivitesinin artırılması için bileşimler. | |
RU2018108589A (ru) | Лечение рака поджелудочной железы и немелкоклеточного рака легкого ингибиторами atr | |
MXPA06008293A (es) | Formulaciones topicas de coenzima q10 y metodos de uso. | |
EA201500905A1 (ru) | Биологически активные молекулы, их конъюгаты и терапевтическое использование | |
BRPI0608175A2 (pt) | método de eliminação de população de células heterogêneas ou mistas em tumores, assim como compostos maitansinóides | |
WO2012094679A3 (en) | Compositions and methods for delivery of high-affinity oxygen binding agents to tumors | |
EA200601630A1 (ru) | Ниосома, имеющая внедрённый в неё маталлопорфириновый комплекс, способ её получения и лекарственное средство с её использованием | |
MX2010000474A (es) | Inhibidores de proteina serina/treonina quinasa a/proteina quinasa b con actividad antitumoral. | |
WO2007147128A3 (en) | Non-toxic anti-cancer drug combining ascorbate, magnesium and a naphthoquinone | |
Song et al. | Nanomaterials-based tumor microenvironment modulation for magnifying sonodynamic therapy | |
Tsivileva et al. | Selenium compounds biotransformed by mushrooms: not only dietary sources, but also toxicity mediators | |
EA201391006A1 (ru) | Гипотоническая водная композиция с пониженным содержанием хлора и с или без фосфолипидов | |
Wang et al. | Degradable nanocatalyst enables antitumor/antibacterial therapy and promotion of wound healing for diabetes via self-enhanced cascading reaction | |
DE602004016950D1 (de) | Verwendung von cyclin-d1-hemmern zur brustkrebsbehandlung | |
CN106421810A (zh) | 一种肿瘤靶向细胞药物载体及其应用 | |
Tian et al. | An Intelligent Cupreous Nanoplatform with Self-Supplied H2O2 and Cu2+/Cu+ Conversion to Boost Cuproptosis and Chemodynamic Combined Therapy | |
RU2009116833A (ru) | Содержащий g-csf агент для предупреждения и лечения диабетической периферической нейропатии | |
WO2004024062A3 (en) | Platinum complexes as antitumor agents in combination with biochemical modulation | |
EA200601471A1 (ru) | Ингибиторы клеточной пролиферации клеток (варианты), фармацевтическая композиция на их основе, способ уничтожения раковых клеток (варианты) и способ лечения и профилактики злокачественных состояний (варианты) | |
CN108159044A (zh) | 抗坏血酸与二甲双胍的复合制剂用于制备化疗药物的应用 | |
RU2008130457A (ru) | Опухолевая вакцина, содержащая аллогенные или ксеногенные опухолевые клетки | |
CN107961209A (zh) | 一种美白抗衰老的护肤品及其制备方法 | |
RU2014120179A (ru) | Терапевтическая комбинация для лечения рака |